Abstract
(-)-Stepholidine (SPD), a natural product isolated from the Chinese herb Stephania, possesses dopamine (DA) D1 partial agonistic and D2 antagonistic properties in the nigrostriatal and mesocorticolimbic DAergic pathways. These unique dual effects have suggested that SPD can effectively restore previously imbalanced functional linkage between D1 and D2 receptors under schizophrenic conditions, in which, SPD improves both the negative and positive symptoms of schizophrenia. SPD also relieves the motor symptoms of Parkinsons disease (PD) when co-administered with Levodopa. Furthermore, SPD exhibits neuroprotective effects through an antioxidative mechanism and slows down the progression of neuronal degeneration in the substantia nigra (SN) of PD patients and/or animal models. Therefore, SPD is a novel, natural compound with potentially therapeutic roles in the treatment of schizophrenia and/or PD.
Keywords: Stepholidine, dopamine D1 receptor, dopamine D2 receptor, schizophrenia, Parkinson's disease
Current Neuropharmacology
Title: The Neuropharmacology of (-)-Stepholidine and its Potential Applications
Volume: 5 Issue: 4
Author(s): Kechun Yang, Guozhang Jin and Jie Wu
Affiliation:
Keywords: Stepholidine, dopamine D1 receptor, dopamine D2 receptor, schizophrenia, Parkinson's disease
Abstract: (-)-Stepholidine (SPD), a natural product isolated from the Chinese herb Stephania, possesses dopamine (DA) D1 partial agonistic and D2 antagonistic properties in the nigrostriatal and mesocorticolimbic DAergic pathways. These unique dual effects have suggested that SPD can effectively restore previously imbalanced functional linkage between D1 and D2 receptors under schizophrenic conditions, in which, SPD improves both the negative and positive symptoms of schizophrenia. SPD also relieves the motor symptoms of Parkinsons disease (PD) when co-administered with Levodopa. Furthermore, SPD exhibits neuroprotective effects through an antioxidative mechanism and slows down the progression of neuronal degeneration in the substantia nigra (SN) of PD patients and/or animal models. Therefore, SPD is a novel, natural compound with potentially therapeutic roles in the treatment of schizophrenia and/or PD.
Export Options
About this article
Cite this article as:
Yang Kechun, Jin Guozhang and Wu Jie, The Neuropharmacology of (-)-Stepholidine and its Potential Applications, Current Neuropharmacology 2007; 5 (4) . https://dx.doi.org/10.2174/157015907782793649
DOI https://dx.doi.org/10.2174/157015907782793649 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Therapeutic Strategies for Huntingtons Disease: From the Bench to the Clinic
Current Psychopharmacology Role of Cyclic Tertiary Amine Bioactivation to Reactive Iminium Species: Structure Toxicity Relationship
Current Drug Metabolism Disruption of the Keap1-Containing Ubiquitination Complex as an Antioxidant Therapy
Current Topics in Medicinal Chemistry Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Current Medicinal Chemistry Is rTMS an Effective Therapeutic Strategy that Can Be Used to Treat Parkinson's Disease?
CNS & Neurological Disorders - Drug Targets Theories and Treatment of Drug Dependency: A Neurochemical Perspective
Current Molecular Pharmacology Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson’s Disease
Current Neuropharmacology Organometallic Complexes: New Tools for Chemotherapy
Current Medicinal Chemistry Pharmacology of Sigma (σ) Receptor Ligands from a Behavioral Perspective
Current Pharmaceutical Design Recent Medicinal Chemistry Studies for Multitarget Agents-Part II
Current Drug Targets Burden of Bronchiectasis in Indigenous Peoples - How Can it be Improved?
Current Pediatric Reviews Current Status of Tyrosine Hydroxylase in Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Subject Index to Volume 4
Current Topics in Medicinal Chemistry Dietary Phytoestrogens: Neuroprotective Role in Parkinson’s Disease
Current Neurovascular Research Medications Affecting Functional Status in Older Persons
Current Pharmaceutical Design Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System
Current Medicinal Chemistry Omega-3 Fatty Acids: Role in the Prevention and Treatment of Psychiatric Disorders
Current Psychiatry Reviews Phenytoin Induced Chorea: A Rare Adverse Effect of the Drug
Current Drug Safety The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism